Background: The type, abundance, and location of tumor-infiltrating lymphocytes (TILs) have been associated with prognosis in colorectal cancer (CRC). This study was conducted to assess the prognostic role of TILs and develop a nomogram for accurate prognostication of stage II CRC. Methods: Immunohistochemistry was conducted to assess the densities of intraepithelial and stromal CD3+, CD8+, CD45RO+, and FOXP3+ TILs, and to estimate PD-L1 expression in tumor cells for 168 patients with stage II CRC. The prognostic roles of these features were evaluated using COX regression model, and nomograms were established to stratify patients into low-and high-risk groups and compare the benefit from adjuvant chemotherapy. Results: In univariate analysis, patients with high intraepithelial or stromal CD3+, CD8+, CD45RO+ and FOXP3+ TILs were associated significantly with better relapse-free survival (RFS) and overall survival (OS), except for stromal CD45RO+ TILs. In multivariate analysis, patients with high intraepithelial CD3+ and stromal FOXP3+ TILs were associated with better RFS (p<0.001 and p=0.032, respectively), while only stromal FOXP3+ TILs was an independent prognostic factor for OS (p=0.031). The nomograms were well calibrated and showed a c-index of 0.751 and 0.757 for RFS and OS, respectively. After stratifying into low-and high-risk groups, the high-risk group exhibited a better OS from adjuvant chemotherapy (3-year OS of 81.9% vs 34.3%, p=0.006). Conclusion: These results may help improve the prognostication of stage II CRC and identify a high-risk subset of patients who appeared to benefit from adjuvant chemotherapy.
Introduction 5-fluorouracil-based adjuvant chemotherapy has been well established for patients with stage III colorectal cancer (CRC), but in stage II CRC, adjuvant chemotherapy is still hotly disputed considering the cost, toxicity, and limited survival benefit. [1] [2] [3] [4] A number of clinicopathological features (poor histological differentiation, T4 stage, <12 nodes harvested, high preoperative carcinoembryonic antigen (CEA) level, intestinal obstruction or perforation, and the presence of lymphovascular or perineural invasion) have been identified assisting the decision for adjuvant chemotherapy in stage II disease. 1, 5, 6 However, only T4 stage has been proven to help identify a specific subset of stage II CRC patients who could achieve survival benefit from adjuvant chemotherapy. 7 Besides, some polygene signatures have been widely explored, 8, 9 but there is still a long way to put these results into clinical practice. Identifying novel biomarkers to filter out the high-risk group of stage II CRC which could benefit from adjuvant chemotherapy is badly needed. Adaptive immune response has been proven to influence the biological behavior of tumor cells, and the immune microenvironment formed by the type, abundance, and location of immune cells within tumor tissues were found to be a better predictor of patient survival than traditional clinicopathological features. 10 Naito et al 11 first demonstrated that the infiltration of tumor nests by CD8+ T-cells was a novel prognostic factor contributing to a better survival in CRC. Thereafter, CD3+ tumor-infiltrating lymphocytes (TILs) have been identified to be associated with favorable prognosis and a lower risk of metachronous metastasis in CRC. 12, 13 CD45RO+ TILs have also been reported to have prognostic significance. Pages et al 14 revealed that high levels of CD45RO+ TILs were correlated with the absence of signs of early metastatic invasion, a less advanced pathological stage, and increased survival. In early-stage CRC, patients with a strong infiltration of CD45RO+ T-cells exhibited an increased expression of T-helper 1 and cytotoxicityrelated genes and helped predict tumor recurrence and survival. 15 Regulatory T-cells engage in the maintenance of immunological self-tolerance by actively suppressing selfreactive lymphocytes. 16, 17 Nuclear transcription factor FOXP3, as a key regulatory gene for the development of regulatory T-cells, has been proven to be associated with improved survival in CRC. 18 Therapeutic antibodies targeting the programmed cell death 1 protein (PD-1) and the programmed death-ligand 1 protein (PD-L1) have been proven to be effective in a number of cancer types. 19, 20 Li et al 21 revealed higher expressions of PD-1 and PD-L1 correlated with better prognosis of CRC patients. The objective of the current study was to assess and compare the prognostic role of PD-L1 and different types of TILs in stage II CRC and construct a nomogram for better prognostication, and to identify the subgroup of stage II CRC patients who can actually benefit from chemotherapy. 
Methods

Study group
Immunohistochemistry (IHC)
Immunohistochemically staining was performed according to standard protocol. Briefly, paraffin-embedded samples were cut into 4 μm sections and placed on polylysinecoated slides. Paraffin sections were baked overnight at 58°C, dewaxed in xylene, rehydrated through a graded series of ethanol, quenched for endogenous peroxidase activity in 0.3% hydrogen peroxide for 15 mins. Antigen retrieval was performed by high-pressure cooking in citrate buffer (pH=6.0) for about 20 mins, then allowed to cool to room temperature, blocking the nonspecific antibody binding sites in 5% normal goat serum for 2 hrs. Sections were incubated at 37°C for 1.5 hrs with rabbit polyclonal antibody against CD3 (1:400, Abcam, ab16669, USA), CD8 (1:400, Cell Signaling Technology, 70306S, USA), CD45RO (1:400, Dako, DK-2600 Glostrup, Denmark), FOXP3 (1:400, Abcam, ab20034, USA), and PD-L1 (1:100, Abcam, ab205921), in a moist chamber. Biotinylated secondary antibody was performed using the EnVision+System-HRP (AEC) (K4005, Dako, Glostrup, Denmark). Subsequently, sections were counterstained with hematoxylin (Sigma-Aldrich, St Louis, MO, USA). TMA slides were scanned by an automated scanning microscope and counted by Image-Pro Plus software (IPP; produced by Media Cybernetics Corporation, USA). Epithelial and stromal areas were calculated separately. Five independent visual fields (at ×400 magnification), representing the most abundant lymphocytic infiltrates, were selected for each patient sample, and we used the mean density to stratify variables into dichotomous data for statistical analysis. PD-L1 expression score was the sum of the cytoplasmic and membrane scores. 22 Cytoplasmic expression level was scored as 0 (negative), 1 (weak), 2 (moderate) or 3 (strong), and membrane expression level was scored as 0 (absent) or 1 (present). PD-L1 scores 2/3/4 were counted as high, scores 0/1 as low. 
Statistical analysis
Results
Immunohistochemical characteristics
Epithelial and in stromal TILs were evaluated separately. Figure 1 . Densities of each T-cell subset (cells/mm 2 ) were distributed as follows: intraepithelial CD3+ (mean 84; range 0-352), stromal CD3+ (mean 376; range 0-1380), intraepithelial CD8+ (mean 60; range 0-344), stromal CD8+ (mean 220; range 0-1120), intraepithelial CD45RO+ (mean 76; range 0-384), stromal CD45RO+ (mean 344; range 0-1600), intraepithelial FOXP3+ (mean 16; range 0-132), and stromal FOXP3+ (mean 132; range 0-600). Seventy-two patients were identified as PD-L1 low, and 96 patients were identified as PD-L1 high.
Correlation of immune biomarkers with clinicopathological and molecular features
Molecular features were available in 129 patients who successfully underwent NGS. As shown in Table 1 , patients with high intraepithelial CD3+, CD45RO+, and stromal FOXP3+ TILs had a significantly higher incidence of normal preoperative CEA (p=0.010, 0.013, and 0.017, respectively). Patients with high intraepithelial FOXP3+ TILs underwent less adjuvant chemotherapy (p=0.019). More colon disease was observed in patients with high intraepithelial CD8+ TILs. Patients with high intraepithelial CD45RO+ and stromal CD8+ TILs had a significantly lower incidence of neural invasion (p=0.043 and 0.046, respectively). More T4 tumors were found in patients with high intraepithelial CD8+ TILs (p=0.025). Patients with high intraepithelial CD45RO+ TILs had a significantly higher incidence of adequate lymph nodes harvested (p=0.005). Patients with high intraepithelial CD8+ and CD45RO+ TILs had a significantly higher incidence of MSI-high (p=0.017 and 0.002, respectively). More ERBB2 mutation were observed in patients with high intraepithelial CD45RO+, FOXP3+, and stromal CD45RO+ TILs (p=0.019, 0.020, and 0.012, respectively). More TP53 mutation were found in patients with high intraepithelial CD8+ and CD45RO+ TILs (p=0.034 and 0.025, respectively). No significant differences were observed for gender, age, histology type, grade, vascular invasion, APC mutation, BRAF mutation, KRAS mutation, NRAS mutation, POLE mutation, PIK3CA mutation, and PTEN mutation.
Prognostic factors
In univariate analysis (Table 2) , for tumor features, CEA was significantly associated with better relapse-free survival (RFS) and overall survival (OS) (p<0.001 and p=0.015, respectively). Number of lymph nodes harvested (LNH) were significantly associated with better OS (p=0.012). Grade reached marginal significance for both RFS and OS (p=0.055 and p=0.068, respectively). For molecular features, BRAF and PTEN mutation were found to be significantly associated with better OS (p=0.007 and p=0.034, respectively), whereas BRAF mutation only reached marginal significance for RFS (p=0.081). For Immune biomarkers, high intraepithelial or stromal CD3+, CD8+, CD45RO+, FOXP3+ TILs were significantly associated with better RFS and OS (all p<0.05), except for high stromal CD45RO+ TILs (p=0.110). PD-L1 was not associated with RFS or OS (p=0.574 and p=0.820, respectively). A multivariate model was developed to test independent prognostic factors for RFS and OS (Table 3 ). In the first model (Model A, n=168), only tumor features and immune biomarkers with a p<0.100 in univariate analysis were included. CEA (p=0.040; RR, 1.591; 95% CI, 1.022-2.495), intraepithelial CD3+ TILs (p<0.001; RR, 0.192; 95% CI, 0.094-0.395), and stromal FOXP3+ TILs (p=0.032; RR, 0.526; 95% CI, 0.292-0.974) were found to be the strongest prognostic factors for RFS, whereas LNH (p=0.010; RR, 0.374; 95% CI, 0178-0.784) and stromal FOXP3+ TILs Figure 2) , we did not establish a nomogram for RFS in Model B due to limited variables in the final model. Calibration curves were exhibited in Figure S1 . For Model A, the nomograms were well calibrated and showed a c-index of 0.751 and 0.757 for RFS and OS, respectively. For Model B, the nomogram for OS was well calibrated and reached a cindex of 0.768. X-tile software was used to select the optimal cutoff values. After stratifying into low-and high-risk groups ( Figure S2) 
Discussion
The therapeutic success of 5-fluorouracil-based adjuvant chemotherapy has been validated in stage III CRC, but not for patients with stage II disease. 24, 25 Up to now, only one nomogram predicting recurrence in stage II CRC has been constructed in literature by Hoshino et al 26 which included sex, carcinoembryonic antigen, tumor location, tumor depth, lymphatic invasion, venous invasion, and number of lymph nodes studied, rendering a c-index of 0.64. In our study, we first introduced immune biomarkers into nomogram construction, achieving a c-index of overwhelming 0.751 and 0.757 for RFS and OS, respectively. Besides, the risk classification based on nomogram could identify a special high-risk subset of stage II CRC patients who may benefit from adjuvant chemotherapy. Accumulating evidence suggests that effector/cytotoxic T-cells (CD3+ 12, 13 and CD8+ 11, 27 ), memory T-cells (CD45RO+ 14, 15 ), and regulatory T-cells (FOXP3+ 16, 18 ) play important roles in antitumor immune response. Thus, the specific subsets of these TILs are thought to be indicators of host immune response to tumor cells and might be a target for immunotherapy. 28, 29 In the current study, we utilized a digitized, high-resolution image analysis system to count the number of TILs, and the mean densities of T-cell subsets were comparable with previous studies (CD3+, 10, 30 CD8+, 18, 31 CD45RO+, 18, 32 and FOXP3+ 30, 31 ). Previous studies have demonstrated the high density of CD3+, CD8+, CD45RO+, or FOXP3+ TILs with MSI-high. 18, 30, 33, 34 In the current study, high densities of CD45RO+ and CD8+ cells, but not that of CD3+ or FOXP3+ cells, are significantly associated with MSI-high. We used multivariate analysis to assess the prognostic roles of these immune biomarkers and found intraepithelial CD3+ TILs and stromal FOXP3+ TILs were the strongest prognostic factors for RFS, whereas only stromal FOXP3+ TILs were an independent prognostic factor for OS. Our study revealed patients with high intraepithelial CD3+ and stromal FOXP3+ TILs had a significantly higher incidence of normal preoperative CEA, which partially explained the good prognosis associated with these biomarkers. Although Li et al 21 concluded PD-L1 correlated with better prognosis in CRC patients, our study did not prove the prognostic role PD-L1, which is in agreement with Masugi's 22 study.
Despite numerous studies have demonstrated the prognostic roles of immune-related biomarkers using IHC, seldom have these studies involved molecular features for analysis. In our study, 129 patients successfully underwent NGS and classic mutations for CRC were evaluated for their prognostic roles. KRAS mutation and PTEN mutation were found to be significant factors for OS in univariate analysis, while only PTEN mutation was demonstrated as an independent prognostic factor in multivariate analysis after adjusting for clinicopathological features and immune biomarkers. PTEN is a candidate tumor suppressor and key negative regulator of the PI3K pathway, involving in cell proliferation, migration, and survival. 35 Somatic mutations in PTEN were detected in about 6% of sporadic CRC, and PTEN mutation was found to be associated with proximal tumors, mucinous histology, MSI-H, CIMP-high, and BRAF mutation. 36 In our study, 8.5% PTEN mutation was observed, 36.4% of MSI-high patients were observed in PTEN mutation group compared with 6.8% in the wild-type group, which is in consistence with previous studies. 36, 37 Recent reports suggest that PTEN exerts an important tumor suppressor role in colorectal carcinogenesis 35 and correlative analyses have associated loss of PTEN with poorer survival, 38, 39 which is in agreement with our study. Our study is limited as a retrospective study in nature, further validations from other institutions are merited. Secondly, we did not separate colon and rectal cancer for further study due to limited sample size. Moreover, considering intratumoral heterogeneity, we admit that our study might still fall short of capturing heterogeneity within tumor. Despite of these shortcomings, this is the largest study elucidating the prognostic roles of the densities of various types of TILs focusing on stage II CRC, and we first used nomogram to visualize the results and stratify patients into low-and high-risk groups. More importantly, it is easier for clinical use than signatures or other risk classification systems. In summary, we constructed nomograms which may help to predict RFS and OS in patients with stage II CRC.
Furthermore, we identified a high-risk subset of stage II CRC patients who appeared to benefit from adjuvant chemotherapy. 
Dovepress
Publish your work in this journal
Cancer Management and Research is an international, peer-reviewed open access journal focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival and quality of life for the cancer patient.
The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.
Submit your manuscript here: https://www.dovepress.com/cancer-management-and-research-journal 
